Semaglutide

Overview

Semaglutide (development code NN9535) is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It is a fully approved prescription medicine, marketed by Novo Nordisk under three brand names with distinct indications: Ozempic (subcutaneous, for type 2 diabetes), Wegovy (subcutaneous, for chronic weight management and, more recently, non-cirrhotic MASH), and Rybelsus (an oral tablet for type 2 diabetes). It is one of the most extensively studied and widely prescribed metabolic medicines of the past decade.

The U.S. Food and Drug Administration (FDA) first approved semaglutide as Ozempic on December 5, 2017 for type 2 diabetes, followed by oral Rybelsus in 2019 and the higher-dose Wegovy formulation for chronic weight management in June 2021. In the European Union it is authorized through the European Medicines Agency (EMA) as Ozempic (2018) and later as Wegovy.

Semaglutide belongs to the same broad incretin-mimetic class as the dual GIP/GLP-1 agonist tirzepatide (approved) and the investigational triple agonist retatrutide. Among GLP-1 receptor agonists, it is notable for once-weekly injectable dosing, large randomized weight-loss data, and a dedicated cardiovascular outcomes trial showing benefit.

Chemistry and structure

Native human GLP-1 is an incretin hormone released from the gut after eating. It has a very short half-life (a few minutes) because it is rapidly cleaved by the enzyme dipeptidyl peptidase-4 (DPP-4) and cleared by the kidneys. Semaglutide is an engineered analog of GLP-1(7-37) designed to resist this degradation and to circulate for days rather than minutes.

Three modifications are central to its design:

• Aib at position 8 — the alanine at position 8 is replaced with α-aminoisobutyric acid (Aib), which protects the molecule against DPP-4 cleavage.
• Arg34 substitution — a lysine-to-arginine change that ensures the fatty-acid side chain attaches at the intended site.
• A C18 fatty-diacid side chain on Lys26 — attached via a short linker, this acyl chain binds tightly but reversibly to serum albumin. Albumin binding shields semaglutide from enzymatic breakdown and renal filtration and effectively extends its residence time, giving a half-life of roughly 7 days.

Oral semaglutide (Rybelsus for type 2 diabetes, and the higher-dose oral Wegovy tablet approved in December 2025 for weight management) is co-formulated with the absorption enhancer SNAC (sodium N-(8-(2-hydroxybenzoyl)amino)caprylate), which transiently raises local gastric pH and permeability to allow a small fraction of the peptide to be absorbed across the stomach lining. Oral bioavailability is low, which is why oral doses differ from injectable doses.

Mechanism of action

Semaglutide activates the GLP-1 receptor, a G-protein-coupled receptor expressed in the pancreas, gastrointestinal tract, and brain. Its metabolic effects arise from several complementary actions:

• Glucose-dependent insulin secretion: it stimulates pancreatic beta cells to release insulin, but only when blood glucose is elevated, which limits the risk of hypoglycemia when used alone.
• Glucagon suppression: it reduces glucagon secretion from pancreatic alpha cells, lowering hepatic glucose output.
• Delayed gastric emptying: food leaves the stomach more slowly, blunting post-meal glucose spikes and prolonging satiety.
• Central appetite regulation: it acts on GLP-1 receptors in the hypothalamus and other brain regions involved in appetite and reward, reducing hunger and food intake. This central effect is the main driver of weight loss.

The combination of reduced appetite, slowed gastric emptying, and improved glucose handling explains both its glycemic and weight effects. The same slowed-gastric-emptying mechanism also underlies many of its gastrointestinal side effects.

Clinical evidence

Semaglutide has been studied in large randomized programs: SUSTAIN (type 2 diabetes, injectable), PIONEER (oral), and STEP (weight management), plus the dedicated cardiovascular outcomes trial SELECT.

SUSTAIN-6 (Marso et al., NEJM 2016). This cardiovascular outcomes trial randomized 3,297 people with type 2 diabetes at high cardiovascular risk to once-weekly semaglutide (0.5 or 1.0 mg) or placebo for 104 weeks. The primary composite outcome (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 6.6% of the semaglutide group versus 8.9% of placebo (hazard ratio 0.74). The trial also reported a higher rate of diabetic retinopathy complications with semaglutide, a signal attributed in part to rapid glucose lowering.

STEP 1 (Wilding et al., NEJM 2021). In 1,961 adults with overweight or obesity but without diabetes, once-weekly semaglutide 2.4 mg plus lifestyle support produced a mean weight loss of 14.9% versus 2.4% with placebo over 68 weeks. About 86% of the semaglutide group lost at least 5% of body weight, and roughly half lost 15% or more.

STEP 4 (Rubino et al., JAMA 2021). After a 20-week run-in on semaglutide, participants who continued the drug lost a further 7.9% of body weight over the next 48 weeks, while those switched to placebo regained about 6.9%, directly demonstrating that ongoing treatment is needed to maintain the effect.

SELECT (Lincoff et al., NEJM 2023). In more than 17,000 adults with overweight or obesity and established cardiovascular disease but without diabetes, semaglutide 2.4 mg reduced the primary composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by about 20% (6.5% vs 8.0% over a mean of roughly 40 months). This established a cardiovascular benefit independent of diabetes.

A separate phase 3 program (ESSENCE) supported the 2025 approval of Wegovy for non-cirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate-to-advanced fibrosis, where semaglutide improved liver histology versus placebo.

Safety and risks

Semaglutide is generally considered effective for its approved uses, but it carries real risks that should be weighed honestly. The following reflects the FDA prescribing information and trial data.

Gastrointestinal effects (most common). Nausea, vomiting, diarrhea, constipation, and abdominal pain are the most frequent side effects, driven largely by delayed gastric emptying. They are usually most intense during dose escalation and tend to ease over time, but they are a common reason for stopping treatment.

Gallbladder disease. Rapid weight loss and the drug itself are associated with an increased rate of gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis). This was seen more often with semaglutide than placebo in the STEP trials.

Pancreatitis. Acute pancreatitis has been reported with GLP-1 receptor agonists. The labels advise discontinuing the drug if pancreatitis is suspected. A clear causal increase has not been firmly established across the class, but the signal warrants caution, especially in people with a history of pancreatitis.

Ileus and gastrointestinal motility. In September 2023, the FDA updated the Ozempic label to add ileus (intestinal obstruction/paralysis) to the adverse-reaction section based on post-marketing reports. Cases of severe gastroparesis (very delayed stomach emptying) have also been reported. These appear uncommon but can be serious.

Muscle and lean-mass loss. As with most substantial weight loss, a portion of the weight lost is lean (including muscle) mass, not just fat. Body-composition data are mixed (some analyses show preserved or improved fat-to-lean ratios overall), but loss of lean mass is a recognized concern, particularly in older adults, and is an active area of research (including studies pairing GLP-1 drugs with resistance exercise or muscle-preserving agents).

Other label cautions. Acute kidney injury (often secondary to dehydration from vomiting/diarrhea), diabetic retinopathy complications in people with diabetes (notably in SUSTAIN-6), hypoglycemia when combined with insulin or sulfonylureas, gallbladder disease, increased heart rate, and hypersensitivity reactions. Semaglutide is not recommended in pregnancy and should be stopped well before a planned pregnancy because of its long half-life.

Contraindications (per FDA label):

• Personal or family history of medullary thyroid carcinoma (MTC).
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
• Known serious hypersensitivity to semaglutide or any excipient.

Discontinuation and weight regain. Semaglutide treats obesity and diabetes as chronic conditions; it does not cure them. As STEP 4 and the STEP 1 extension showed, appetite and weight tend to return after stopping: participants in the STEP 1 extension regained about two-thirds of their lost weight within a year of discontinuation. This makes semaglutide, in practice, a long-term therapy for most people who benefit from it.

Regulatory status

United States (FDA — approved):

• December 5, 2017: Ozempic (subcutaneous) approved for type 2 diabetes; later expanded to include cardiovascular risk reduction and reduced risk of kidney decline.
• 2019: Rybelsus (oral) approved for type 2 diabetes.
• June 2021: Wegovy (subcutaneous, 2.4 mg) approved for chronic weight management.
• 2024: Wegovy gained an indication to reduce cardiovascular events in adults with established cardiovascular disease and overweight/obesity (based on SELECT).
• August 15, 2025: Wegovy received accelerated approval for non-cirrhotic MASH with moderate-to-advanced (F2-F3) fibrosis.
• December 22, 2025: An oral Wegovy tablet (once-daily oral semaglutide 25 mg) was approved for chronic weight management and cardiovascular risk reduction, the first oral GLP-1 receptor agonist approved for weight loss. This is a higher-dose oral product distinct from Rybelsus (the oral diabetes formulation). In the OASIS 4 trial it produced roughly 16.6% mean weight loss when adhered to.

European Union (EMA — approved):

• Ozempic authorized via the EMA in 2018 for type 2 diabetes; Wegovy later authorized for weight management. Semaglutide is also recognized in the EU for cardiovascular benefit, with additional formulations and indications (including oral weight-management and MASH) progressing through the regulatory process.

Across both regions, semaglutide is a prescription-only medicine. It is not approved for cosmetic use, bodybuilding, or casual weight loss outside its defined indications, and material sold outside the regulated pharmacy supply chain is not the approved product.

How it compares

Semaglutide is one of several incretin-based therapies. The table below is factual and neutral and does not rank these agents.

Important context: cross-trial weight-loss percentages are not directly comparable because trial populations, durations, and designs differ. In the head-to-head SURMOUNT/SURPASS-era comparisons, tirzepatide generally produced greater average weight loss than semaglutide, but both are approved and effective. Retatrutide's higher phase 2 numbers come from an early, smaller, investigational trial and should not be read as established or approved efficacy. Side-effect profiles across the class are broadly similar (predominantly gastrointestinal), and all share the rodent thyroid C-cell tumor warning.

Common misconceptions

---

This article is provided for educational purposes only and is not medical advice. Semaglutide (Ozempic, Wegovy, Rybelsus) is a prescription medication that should be used only under the supervision of a qualified healthcare professional, who can assess contraindications such as MEN2/medullary thyroid carcinoma, manage side effects, and provide appropriate monitoring. Nothing here should be interpreted as encouragement to obtain or use semaglutide outside of an approved, supervised clinical context.

Community claims & recent evidence

These points address claims circulating in the peptide community — including popular video "masterclasses" that pit semaglutide against triple agonists — checked against the primary sources we could reach. A knowledgeable creator is not peer review, so every statement was treated as a claim to check against a locatable primary source. But a caveat cuts both ways: not finding a citation here does not make a claim false. A great deal of relevant research is not indexed in the databases we searched — paywalled journals, regional (including Russian- and Chinese-language) literature, conference abstracts, clinician experience, and unpublished or proprietary data — so where we could not trace a figure, we say only that, and no more.

Verified additions

• Body composition improves; it does not merely shrink. In the STEP 1 DEXA sub-study, 68 weeks of semaglutide 2.4 mg reduced total fat mass by 19.3% and visceral fat by 27.4% while lean body mass fell only 9.7%, so the lean share of total body mass actually rose by ~3.0 percentage points. [Human] (Wilding et al., Journal of the Endocrine Society 2021)
• Semaglutide measurably lowers inflammation. Across STEP 1/2/3, semaglutide 2.4 mg reduced high-sensitivity C-reactive protein (a systemic inflammation marker) by roughly 44%, 39%, and 48% versus placebo — largely, though perhaps not entirely, mediated by weight loss. [Human] (Verma et al., eClinicalMedicine 2022)
• Why lean-mass loss is worth tracking at all: skeletal muscle is the body's dominant glucose sink, taking up ~80% of insulin-stimulated glucose via GLUT4 — the physiological reason preserving lean mass during any weight loss matters. [Human] (DeFronzo & Tripathy, Diabetes Care 2009)
• Semaglutide was actually tested against Alzheimer's — and did not slow it. The phase 3 evoke/evoke+ trials (3,808 adults with early-stage Alzheimer's) found oral semaglutide did not slow clinical progression on CDR-SB versus placebo (estimated difference −0.08, p=0.57; +0.10, p=0.46), despite improving some AD biomarkers. [Human] (Cummings et al., The Lancet 2026)

Claims we could not reconcile with the trial data we found

• "70% (or 50%) of the weight lost on semaglutide is muscle and connective tissue." The DEXA data point the other way: lean mass made up roughly 40% of the weight lost — the expected fraction for weight loss in general — and the lean-to-total ratio improved rather than worsened (see above). We could not trace the cited "JAMA Network Open, 50% fat-free mass" figure to any identifiable published semaglutide study, and the 70% figure runs counter to the body-composition trial above. That does not prove the higher numbers originate nowhere real — only that we could not locate their source in the literature accessible to us, so we weight them against the trial we can read rather than treating them as established. [Human]
• "It's metabolic duct tape that makes the underlying disease infinitely worse and leaves you more diabetic." The controlled human data available to us point the other way: semaglutide durably lowers HbA1c and reduces cardiovascular events — MACE hazard ratio 0.74 in type 2 diabetes (SUSTAIN-6, Marso et al., NEJM 2016) and a ~20% reduction in obesity without diabetes (SELECT, Lincoff et al., NEJM 2023). On the endpoints these trials measured, glycemic control and cardiovascular risk improved rather than worsened. [Human]
• "GLP-1 drugs are bystanders to inflammation — they do nothing at the source." Semaglutide cut CRP by ~40–48% across the STEP program (Verma et al., eClinicalMedicine 2022), so at least on that marker the "no anti-inflammatory effect at all" framing is not what its own trial data show; whether the effect reaches inflammation "at the source" independent of weight loss is a separate, still-open mechanistic question. [Human]
• "Triple agonists reverse Alzheimer's/dementia ('type 3 diabetes') while GLP-1s do nothing for the brain." The attribution appears backwards on the evidence we can see: it is semaglutide — a GLP-1 — that reached phase 3 for early Alzheimer's (evoke/evoke+), and it did not slow progression (Cummings et al., Lancet 2026). We found no completed Alzheimer's outcome trial for any triple agonist, and no human demonstration of dementia reversal for either class — which reflects what has been published and reached us, not a guarantee that no such work exists; that claim therefore remains [Hypothesis]. [Human]